2-(bromomethyl)-5-cyclopropyl-1,3,4-thiadiazole | 951122-65-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(bromomethyl)-5-cyclopropyl-1,3,4-thiadiazole
• CAS: 951122-65-9
• 化学式: C₆H₇BrN₂S
• 分子量: 219.105
• InChiKey: NJNWHEMXTWUORQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-propyl-4-(trifluoromethyl)-1H-indole-5-carbonitrile 、 2-(bromomethyl)-5-cyclopropyl-1,3,4-thiadiazole 在 caesium carbonate 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以61%的产率得到1-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]-2-propyl-4-(trifluoromethyl)-1H-indole-5-carbonitrile
  参考文献：
  名称：

  WO2008/42571

  摘要：

  公开号：
• 作为产物：
  描述：

  ethyl 5-cyclopropyl-1,3,4-thiadiazole-2-carboxylate 在 sodium tetrahydroborate 、 四溴化碳 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 12.5h， 生成 2-(bromomethyl)-5-cyclopropyl-1,3,4-thiadiazole
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  [FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2018119395A8

文献信息

• CHEMICAL COMPOUNDS
  申请人：Turnbull Philip Stewart

  公开号：US20090264482A1

  公开（公告）日：2009-10-22

  This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.

  本发明涉及非类固醇化合物，它们是雄激素受体的调节剂，以及制备和使用这种化合物的方法。
• Chemical compounds
  申请人：SmithKline Beecham Corporation

  公开号：US07572820B2

  公开（公告）日：2009-08-11

  This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.

  本发明涉及非类固醇化合物，它们是雄激素受体的调节剂，以及制备和使用这些化合物的方法。
• ANTIBACTERIAL AGENTS
  申请人：Brown David Ryall

  公开号：US20100173933A1

  公开（公告）日：2010-07-08

  Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R 1 )— or ═N—; R 1 is hydrogen or an optional substituent and R 2 is hydrogen, methyl, or fluorine; or R 1 and R 2 taken together are —CH 2 —, —CH 2 CH 2 —, —O—, or, in either orientation, —O—CH 2 — or —OCH 2 CH 2 —; R 3 is a radical of formula -(Alk 1 ) m -(Z) p -(Alk 2 ) n -Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(═O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk 1 and Alk 2 are optionally substituted C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, or —N(CH 2 CH 3 )—; and Q is hydrogen, halogen, nitrile, or hydroxyl or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms.

  化学式为（I）的化合物具有抗菌活性：其中R代表氢或1、2或3个可选取代基；W是═C（R1）-或═N-；R1是氢或可选取代基，R2是氢、甲基或氟；或R1和R2一起取-CH2-、- -、-O-，或者，在任何方向上，取-O- -或-O -；R3是公式-(Alk1)m-(Z)p-(Alk2)n-Q的基团，其中m、p和n独立地为0或1，但至少有一个为1，Z是-O-、-S-、-S（O）-、-S（O2）-、-NH-、-N（CH3）-、-N（ ）-、-C（═O）-、-O-（C═O）-、-C（═O）-O-，或具有3至6个环原子的可选取代的单环碳环或杂环基团；或具有5至10个环原子的可选取代双环杂环基团；Alk1和Alk2是可选取代的C1-C6烷基、C2-C6烯基或C2-C6炔基基团，可以以-O-、-S-、-S（O）-、-S（O2）-、-NH-、-N（ ）-或-N（ ）-结尾或被中断；Q是氢、卤素、腈或羟基，或具有3至6个环原子的可选取代的单环碳环或杂环基团；或具有5至10个环原子的可选取代的双环杂环基团。
• In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses
  作者：Yuanxiang Wang、Yanmei Hu、Shuting Xu、Yongtao Zhang、Rami Musharrafieh、Raymond Kin Hau、Chunlong Ma、Jun Wang

  DOI：10.1021/acs.jmedchem.7b01536

  日期：2018.2.8

  Influenza viruses are respiratory pathogens that are responsible for both seasonal influenza epidemics and occasional influenza pandemics. The narrow therapeutic window of oseltamivir, coupled with the emergence of drug resistance, calls for the next-generation of antivirals. With our continuous interest in developing AM2-S31N inhibitors as oral influenza antivirals, we report here the progress of optimizing the in vitro pharmacokinetic (PK) properties of AM2-S31N inhibitors. Several AM2-S31N inhibitors, including compound 10b, were discovered to have potent channel blockage, single to submicromolar antiviral activity, and favorable in vitro PK properties. The antiviral efficacy of compound 10b was also synergistic with oseltamivir carboxylate. Interestingly, binding kinetic studies (K-d, K-on, and K-off) revealed several AM2-S31N inhibitors that have similar K-d values but significantly different K-on and K-off values. Overall, this study identified a potent lead compound (10b) with improved in vitro PK properties that is suitable for the in vivo mouse model studies.
• SUBSTITUTED INDOLE COMPOUNDS
  申请人：SmithKline Beecham Corporation

  公开号：EP2079466A2

  公开（公告）日：2009-07-22